Molecule
Sodium nitroprusside is a vasodilator indicated for immediate reduction of blood pressure, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Sodium nitroprusside for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure. • Producing controlled hypotension to reduce bleeding during surgery. • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure.
Source: US FDA prescribing information
Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries, but this selectivity is much less marked than that of nitroglycerin. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload).
Source: US FDA prescribing information
Initiate infusion of sodium nitroprusside at a rate of 0.3 mcg/kg/min, and titrate every few minutes until the desired effect is achieved OR the maximum recommended infusion rate of 10 mcg/kg/min has been reached.
Source: US FDA prescribing information
• Diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting). • Inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) coming to emergency surgery. • Patients with congenital (Leber’s) optic atrophy or with tobacco amblyopia. • Acute heart failure associated with reduced peripheral vascular resistance. • Concomitant use with sildenafil, tadalafil, vardenifil, or riociguat. • Diseases with compensatory hypertension (e.g. coarctation of the aorta, arteriovenous shunting). • Inadequate cerebral circulation or moribund patients (A.S.A. Class 5E) coming to emergency surgery. • Congenital (Leber’s) optic atrophy or tobacco amblyopia.
Source: US FDA prescribing information
Boxed warning ((a) excessive hypotension, (b) cyanide toxicity (a) excessive hypotension): Sodium Nitroprusside can cause precipitous decreases in blood pressure which can lead to irreversible ischemic injuries or death. Use only with continuous blood pressure monitoring. • Thiocynate toxicity. • Methemoglobinemia. • Increases in intracranial pressure. • Diminished capacity to compensate for anemia and hypovolemia with anesthesia during surgery
Source: US FDA prescribing information
The following adverse reactions are described, or described in greater detail, in other sections: • Hypotension • Cyanide Toxicity • Thiocyanate Toxicity • Methemoglobinemia • Increased Intracranial Pressure • Anemia and Hypovolemia Less common adverse reactions include: Cardiovascular: Bradycardia, electrocardiographic changes, tachycardia, palpitations, retrosternal discomfort Dermatologic: Rash Endocrine: Hypothyroidism Gastrointestinal: Ileus, nausea, abdominal pain Hematologic: Decreased platelet aggregation Musculoskelatal: Muscle twitching Neurologic: Increased intracranial pressure, dizziness, headache Miscellaneous: Flushing, diaphoresis, venous streaking, irritation at the infusion site Most common adverse reactions are hypotension and cyanide toxicity.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F). To protect NIPRIDE ® RTU from light, vial should be stored in its carton until used.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Sodium nitroprusside, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sodium nitroprusside 50 mg/2 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium nitroprusside 10 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium nitroprusside 20 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Sodium nitroprusside 50 mg/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Nipride Rtu 20 mg/100 mL injectionIntravenous | Exela Pharma Sciences | US FDA | Available on request |
| Nipride Rtu 50 mg/100 mL injectionIntravenous | Exela Pharma Sciences | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 10 May 1974 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 6 presentations of Sodium nitroprusside and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Sodium nitroprusside, including Nipride Rtu.
Yes. The US FDA first approved Sodium nitroprusside on 10 May 1974, according to Drugs@FDA.
No listed presentation of Sodium nitroprusside is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.